Astellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week High – Still a Buy?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $11.96 and last traded at $11.94, with a volume of 5026 shares changing hands. The stock had previously closed at $11.64.

Analyst Ratings Changes

ALPMY has been the subject of several recent research reports. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Sanford C. Bernstein downgraded shares of Astellas Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 2nd. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, Astellas Pharma has a consensus rating of “Hold”.

Astellas Pharma Trading Up 3.2%

The company has a 50 day moving average of $11.01 and a 200 day moving average of $10.38. The firm has a market cap of $21.73 billion, a price-to-earnings ratio of 25.55 and a beta of 0.23. The company has a current ratio of 1.17, a quick ratio of 0.89 and a debt-to-equity ratio of 0.38.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.10. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.73%. The company had revenue of $3.45 billion for the quarter, compared to the consensus estimate of $3.14 billion. As a group, research analysts anticipate that Astellas Pharma Inc. will post 0.42 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.